These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

613 related articles for article (PubMed ID: 18410893)

  • 1. Preengraftment serum C-reactive protein (CRP) value may predict acute graft-versus-host disease and nonrelapse mortality after allogeneic hematopoietic stem cell transplantation.
    Fuji S; Kim SW; Fukuda T; Mori S; Yamasaki S; Morita-Hoshi Y; Ohara-Waki F; Heike Y; Tobinai K; Tanosaki R; Takaue Y
    Biol Blood Marrow Transplant; 2008 May; 14(5):510-7. PubMed ID: 18410893
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Successful prevention of acute graft-versus-host disease using low-dose antithymocyte globulin after mismatched, unrelated, hematopoietic stem cell transplantation for acute myelogenous leukemia.
    Kim HJ; Min WS; Cho BS; Eom KS; Kim YJ; Min CK; Lee S; Cho SG; Jin JY; Lee JW; Kim CC
    Biol Blood Marrow Transplant; 2009 Jun; 15(6):704-17. PubMed ID: 19450755
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Patterns of C-reactive protein release following allogeneic stem cell transplantation are correlated with leukemic relapse.
    Min CK; Kim SY; Eom KS; Kim YJ; Kim HJ; Lee S; Kim DW; Lee JW; Min WS; Kim CC
    Bone Marrow Transplant; 2006 Mar; 37(5):493-8. PubMed ID: 16435015
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparable antileukemia/lymphoma effects in nonremission patients undergoing allogeneic hematopoietic cell transplantation with a conventional cytoreductive or reduced-intensity regimen.
    Maruyama D; Fukuda T; Kato R; Yamasaki S; Usui E; Morita-Hoshi Y; Kim SW; Mori S; Heike Y; Makimoto A; Tajima K; Tanosaki R; Tobinai K; Takaue Y
    Biol Blood Marrow Transplant; 2007 Aug; 13(8):932-41. PubMed ID: 17640597
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Early elevation of C-reactive protein correlates with severe infection and nonrelapse mortality in children undergoing allogeneic stem cell transplantation.
    McNeer JL; Kletzel M; Rademaker A; Alford K; O'Day K; Schaefer C; Duerst R; Jacobsohn DA
    Biol Blood Marrow Transplant; 2010 Mar; 16(3):350-7. PubMed ID: 20005964
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Influence of pretransplantation serum ferritin on nonrelapse mortality after myeloablative and nonmyeloablative allogeneic hematopoietic stem cell transplantation.
    Kataoka K; Nannya Y; Hangaishi A; Imai Y; Chiba S; Takahashi T; Kurokawa M
    Biol Blood Marrow Transplant; 2009 Feb; 15(2):195-204. PubMed ID: 19167679
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Analysis of risk factors for the development of acute graft-versus-host disease in 151 cases of allo-hematopoietic stem cell transplantation].
    Chen Y; Lu DP; Liu KY; Dong LJ; Ren HY; Huang XJ; Chen H; Liu DH; Jiang Q; Chen YH; Xu LP; Zhang YC; Lu J; Gao ZY
    Zhonghua Xue Ye Xue Za Zhi; 2005 Feb; 26(2):74-7. PubMed ID: 15921621
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Methotrexate Reduces the Incidence of Severe Acute Graft-versus-Host Disease without Increasing the Risk of Relapse after Reduced-Intensity Allogeneic Stem Cell Transplantation from Unrelated Donors.
    Vigouroux S; Tabrizi R; Melot C; Coiffard J; Lafarge X; Marit G; Bouabdallah K; Pigneux A; Leguay T; Dilhuydy MS; Schmitt A; Boiron JM; Milpied N
    Biol Blood Marrow Transplant; 2011 Jan; 17(1):93-100. PubMed ID: 20601038
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Hyperglycemia during the neutropenic period is associated with a poor outcome in patients undergoing myeloablative allogeneic hematopoietic stem cell transplantation.
    Fuji S; Kim SW; Mori S; Fukuda T; Kamiya S; Yamasaki S; Morita-Hoshi Y; Ohara-Waki F; Honda O; Kuwahara S; Tanosaki R; Heike Y; Tobinai K; Takaue Y
    Transplantation; 2007 Oct; 84(7):814-20. PubMed ID: 17984832
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Hematopoietic stem cell transplantation after reduced intensity conditioning in acute myelogenous leukemia patients older than 40 years.
    Huisman C; Meijer E; Petersen EJ; Lokhorst HM; Verdonck LF
    Biol Blood Marrow Transplant; 2008 Feb; 14(2):181-6. PubMed ID: 18215778
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Hematopoietic cell transplantation from an HLA-mismatched familial donor is feasible without ex vivo-T cell depletion after reduced-intensity conditioning with busulfan, fludarabine, and antithymocyte globulin.
    Lee KH; Lee JH; Lee JH; Kim DY; Kim SH; Shin HJ; Lee YS; Kang YA; Seol M; Ryu SG
    Biol Blood Marrow Transplant; 2009 Jan; 15(1):61-72. PubMed ID: 19135944
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prognostic factors identifiable at the time of onset of acute graft-versus-host disease after allogeneic hematopoietic cell transplantation.
    Lee KH; Choi SJ; Lee JH; Lee JS; Kim WK; Lee KB; Sohn SK; Kim JG; Kim DH; Seol M; Lee YS; Lee JH
    Haematologica; 2005 Jul; 90(7):939-48. PubMed ID: 15996932
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Excellent outcome of allogeneic hematopoietic stem cell transplantation using a conditioning regimen with medium-dose VP-16, cyclophosphamide and total-body irradiation for adult patients with acute lymphoblastic leukemia.
    Shigematsu A; Kondo T; Yamamoto S; Sugita J; Onozawa M; Kahata K; Endo T; Shiratori S; Ota S; Obara M; Wakasa K; Takahata M; Takeda Y; Tanaka J; Hashino S; Nishio M; Koike T; Asaka M; Imamura M
    Biol Blood Marrow Transplant; 2008 May; 14(5):568-75. PubMed ID: 18410899
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Serum cholinesterase is an early and sensitive marker of graft-versus host-disease (GVHD) and transplant-related mortality (TRM).
    Bacigalupo A; Oneto R; Bruno B; Lamparelli T; Gualandi F; Bregante S; Raiola AM; Di Grazia C; Dominietto A; Lombardi A; Frassoni F; Van Lint MT
    Bone Marrow Transplant; 2001 Dec; 28(11):1041-5. PubMed ID: 11781614
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Risk-factor analysis for predicting progressive- or quiescent-type chronic graft-versus-host disease in a patient cohort with a history of acute graft-versus-host disease after allogeneic stem cell transplantation.
    Sohn SK; Kim DH; Baek JH; Kim JG; Lee KB; Lee KH; Lee JH; Choi SJ; Lee JH; Shin IH
    Bone Marrow Transplant; 2006 Apr; 37(7):699-708. PubMed ID: 16501588
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparison between an artificial neural network and logistic regression in predicting acute graft-vs-host disease after unrelated donor hematopoietic stem cell transplantation in thalassemia patients.
    Caocci G; Baccoli R; Vacca A; Mastronuzzi A; Bertaina A; Piras E; Littera R; Locatelli F; Carcassi C; La Nasa G
    Exp Hematol; 2010 May; 38(5):426-33. PubMed ID: 20206661
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prognostic value of T-1 cell numbers prior to allogeneic stem cell transplantation in patients with severe graft-versus-host disease.
    Banning U; Lange T; Krahl R; Mauz-Körholz C; Krutmann J; Niederwieser D; Körholz D
    Bone Marrow Transplant; 2005 Apr; 35(7):691-7. PubMed ID: 15696178
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Haploidentical allogeneic hematopoietic cell transplantation in adults using CD3/CD19 depletion and reduced intensity conditioning: an update.
    Bethge WA; Faul C; Bornhäuser M; Stuhler G; Beelen DW; Lang P; Stelljes M; Vogel W; Hägele M; Handgretinger R; Kanz L
    Blood Cells Mol Dis; 2008; 40(1):13-9. PubMed ID: 17869547
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Allogeneic hematopoietic stem cell transplantation in patients with chronic myeloid leukemia in the Czech Republic--a retrospective analysis of results in years 1988-2005].
    Faber E; Koza V; Vítek A; Mayer J; Sedlácek P; Zák P; Zapletalová J; Benesová K; Krejcová H; Steinerová K; Maresová I; Cetkovský P
    Vnitr Lek; 2006 Dec; 52(12):1172-80. PubMed ID: 17299910
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Risk factors for acute graft-versus-host disease grades II-IV after reduced intensity conditioning allogeneic stem cell transplantation with unrelated donors: a single centre study.
    Remberger M; Mattsson J; Hassan Z; Karlsson N; LeBlanc K; Omazic B; Okas M; Sairafi D; Ringdén O
    Bone Marrow Transplant; 2008 Feb; 41(4):399-405. PubMed ID: 17982493
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 31.